Advertisement

Topics

Radiodermatitis - Pipeline Review, H1 2015

02:29 EDT 22 Jul 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Radiodermatitis - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-06-16. This 45-page report is available in PDF from $2000.

Radiodermatitis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Radiodermatitis - Pipeline Review, H1 2015’, provides an overview of the Radiodermatitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Radiodermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiodermatitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Radiodermatitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Radiodermatitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Radiodermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Radiodermatitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and…

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Radiodermatitis Overview 6
Therapeutics Development 7
Pipeline Products for Radiodermatitis - Overview 7
Pipeline Products for Radiodermatitis - Comparative Analysis 8
Radiodermatitis - Therapeutics under Development by Companies 9
Radiodermatitis - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Radiodermatitis - Products under Development by Companies 12
Radiodermatitis - Companies Involved in Therapeutics Development 13
APEIRON Biologics AG 13
ProCertus BioPharm Inc. 14
Reata Pharmaceuticals, Inc. 15
Stemnion, Inc 16
Vida Therapeutics Inc. 17
Radiodermatitis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
Amnion Derived Cellular Cytokine Solution - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
APN-201 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
PrC-210 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
RTA-408 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
VTI-1000 Series - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Radiodermatitis - Recent Pipeline Updates 36
Radiodermatitis - Dormant Projects 38
Radiodermatitis - Discontinued Products 39
Radiodermatitis - Product Development Milestones 40
Featured News & Press Releases 40
Jul 25, 2014: Reata Enrolls First Patient in the PRIMROSE Study, a Phase 2 Study Examining RTA 408 in Breast Cancer Patients at Risk for Radiation Dermatitis 40
Apr 24, 2014: RTA 408 Lotion Demonstrates Favorable Safety and Pharmacodynamic Response in a Phase 1 Study 40
Apr 10, 2014: Preclinical Study of Reata's RTA 408 Demonstrates Role in Prevention and Treatment of Radiation Dermatitis 41
Mar 05, 2013: Apeiron Biologics's Liposomal Formulation Of Recombinant Superoxide Dismutase Achieves All Endpoints In Clinical Study 41
Aug 22, 2012: Apeiron Biologics Receives €510,000 ZIT Grant For Further Development Of APN201 Project 42
Feb 27, 2012: Apeiron Initiates Clinical Study To Investigate Prevention Of Radiation-Induced Skin Damage In Breast Cancer Patients 42
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45

For more information open Radiodermatitis - Pipeline Review, H1 2015.

SKU: GMDHC6799IDB

Original Article: Radiodermatitis - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Radiodermatitis - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...